Phase 1
Completed N=51
A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects
Healthy Volunteers
Source: ClinicalTrials.gov NCT02155543 ↗
Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Apr 2016
Primary outcomePrimary: Maximal Plasma Concentration (Cmax) of AGN-223575 — 0.186; 0.128; 0.114; NA Nanograms/Milliliters (ng/mL)
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of AGN-223575 in healthy subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximal Plasma Concentration (Cmax) of AGN-223575 |
0.186; 0.128; 0.114; NA | — |
Eligibility Criteria
Inclusion Criteria
- Weight at least 110 lbs
Exclusion Criteria
- Use of contact lenses within 14 days, or planned use during the study
- Use of any ocular eye medications within 30 days, or anticipated use during the study
- Anticipated use of any artificial tears product during the study
Data sourced from ClinicalTrials.gov (NCT02155543). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.